Cargando…

Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument

(1) Background: The UCLA GIT 2.0 questionnaire has been recognized as a feasible and reliable instrument to assess gastrointestinal (GI) symptoms in systemic sclerosis (SSc) patients and their impact on quality of life. The aim of this study was to create and validate UCLA GIT 2.0 for Portuguese pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreira, Pedro L., Genrinho, Inês, Santiago, Tânia, Carones, Adriana, Mazeda, Carolina, Barcelos, Anabela, Beirão, Tiago, Costa, Flávio, Santos, Inês, Couto, Maura, Rato, Maria, Terroso, Georgina, Monteiro, Paulo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865185/
https://www.ncbi.nlm.nih.gov/pubmed/36674306
http://dx.doi.org/10.3390/ijerph20021553
_version_ 1784875773671243776
author Ferreira, Pedro L.
Genrinho, Inês
Santiago, Tânia
Carones, Adriana
Mazeda, Carolina
Barcelos, Anabela
Beirão, Tiago
Costa, Flávio
Santos, Inês
Couto, Maura
Rato, Maria
Terroso, Georgina
Monteiro, Paulo
author_facet Ferreira, Pedro L.
Genrinho, Inês
Santiago, Tânia
Carones, Adriana
Mazeda, Carolina
Barcelos, Anabela
Beirão, Tiago
Costa, Flávio
Santos, Inês
Couto, Maura
Rato, Maria
Terroso, Georgina
Monteiro, Paulo
author_sort Ferreira, Pedro L.
collection PubMed
description (1) Background: The UCLA GIT 2.0 questionnaire has been recognized as a feasible and reliable instrument to assess gastrointestinal (GI) symptoms in systemic sclerosis (SSc) patients and their impact on quality of life. The aim of this study was to create and validate UCLA GIT 2.0 for Portuguese patients with SSc. (2) Methods: A multi-center study was conducted enrolling SSc patients. UCLA GIT 2.0 was validated in Portuguese using reliability (internal consistency, item –total correlation, and reproducibility) and validity (content, construct, and criterion) tests. Criterion tests included EQ-5D and SF-36v2. Social–demographic and clinical data were collected. (3) Results: 102 SSc patients were included, 82.4% of them female, and with a mean sample age of 57.0 ± 12.5 years old. The limited form of SSc was present in 62% of the patients and 56.9% had fewer than five years of disease duration. Almost 60% presented with SSc-GI involvement with a negative impact on quality of life. The means for SF-36v2 were 39.3 ± 10.3 in the physical component summary and 47.5 ± 12.1 in the mental component summary. Total GI score, reported as mild in 57.8% of the patients, was highly reliable (ICC = 0.912) and the Cronbach’s alpha was 0.954. There was a high correlation between the total GI score and EQ-5D-5L and SF-36v2 scores. (4) Conclusion: The Portuguese version of UCLA GIT 2.0 showed good psychometric properties and can be used in research and clinical practice.
format Online
Article
Text
id pubmed-9865185
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98651852023-01-22 Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument Ferreira, Pedro L. Genrinho, Inês Santiago, Tânia Carones, Adriana Mazeda, Carolina Barcelos, Anabela Beirão, Tiago Costa, Flávio Santos, Inês Couto, Maura Rato, Maria Terroso, Georgina Monteiro, Paulo Int J Environ Res Public Health Article (1) Background: The UCLA GIT 2.0 questionnaire has been recognized as a feasible and reliable instrument to assess gastrointestinal (GI) symptoms in systemic sclerosis (SSc) patients and their impact on quality of life. The aim of this study was to create and validate UCLA GIT 2.0 for Portuguese patients with SSc. (2) Methods: A multi-center study was conducted enrolling SSc patients. UCLA GIT 2.0 was validated in Portuguese using reliability (internal consistency, item –total correlation, and reproducibility) and validity (content, construct, and criterion) tests. Criterion tests included EQ-5D and SF-36v2. Social–demographic and clinical data were collected. (3) Results: 102 SSc patients were included, 82.4% of them female, and with a mean sample age of 57.0 ± 12.5 years old. The limited form of SSc was present in 62% of the patients and 56.9% had fewer than five years of disease duration. Almost 60% presented with SSc-GI involvement with a negative impact on quality of life. The means for SF-36v2 were 39.3 ± 10.3 in the physical component summary and 47.5 ± 12.1 in the mental component summary. Total GI score, reported as mild in 57.8% of the patients, was highly reliable (ICC = 0.912) and the Cronbach’s alpha was 0.954. There was a high correlation between the total GI score and EQ-5D-5L and SF-36v2 scores. (4) Conclusion: The Portuguese version of UCLA GIT 2.0 showed good psychometric properties and can be used in research and clinical practice. MDPI 2023-01-14 /pmc/articles/PMC9865185/ /pubmed/36674306 http://dx.doi.org/10.3390/ijerph20021553 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ferreira, Pedro L.
Genrinho, Inês
Santiago, Tânia
Carones, Adriana
Mazeda, Carolina
Barcelos, Anabela
Beirão, Tiago
Costa, Flávio
Santos, Inês
Couto, Maura
Rato, Maria
Terroso, Georgina
Monteiro, Paulo
Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
title Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
title_full Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
title_fullStr Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
title_full_unstemmed Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
title_short Creation and Validation of a Portuguese Version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument
title_sort creation and validation of a portuguese version of the ucla scleroderma clinical trial consortium gastrointestinal tract instrument
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865185/
https://www.ncbi.nlm.nih.gov/pubmed/36674306
http://dx.doi.org/10.3390/ijerph20021553
work_keys_str_mv AT ferreirapedrol creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument
AT genrinhoines creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument
AT santiagotania creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument
AT caronesadriana creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument
AT mazedacarolina creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument
AT barcelosanabela creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument
AT beiraotiago creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument
AT costaflavio creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument
AT santosines creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument
AT coutomaura creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument
AT ratomaria creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument
AT terrosogeorgina creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument
AT monteiropaulo creationandvalidationofaportugueseversionoftheuclasclerodermaclinicaltrialconsortiumgastrointestinaltractinstrument